Get the Stockscreener App
0.00
100.00%
-0.365
After Hours:
.38
0.38
+
Elevation Oncology Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
See More
Previous Close:
$0.365
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$21.63M
Revenue:
-
Net Income/Loss:
$-41.95M
P/E Ratio:
0.00
EPS:
-0.83
Net Cash Flow:
$-38.34M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.98
Elevation Oncology Inc Stock (ELEV) Company Profile
Name
Elevation Oncology Inc
Sector
Industry
Phone
(716) 371-1125
Address
101 FEDERAL STREET, BOSTON
Compare ELEV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.00 | 21.63M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-25 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-21-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-25 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| May-30-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
View All
Elevation Oncology Inc Stock (ELEV) Latest News
How strong is Elevation Oncology Inc. company’s balance sheetTurn market volatility into profit opportunities - Jammu Links News
Is Elevation Oncology Inc. stock overvalued or undervaluedTurn volatility into profit opportunities - Jammu Links News
What institutional investors are buying Elevation Oncology Inc. stockExceptional market positioning - Jammu Links News
Is Elevation Oncology Inc. a growth stock or a value stockCapitalize on momentum stocks early - Jammu Links News
What is Elevation Oncology Inc. company’s growth strategyInvest confidently with real-time data - Jammu Links News
What analysts say about Elevation Oncology Inc. stockHigh-yield capital appreciation - Jammu Links News
What is the risk reward ratio of investing in Elevation Oncology Inc. stockAccess powerful market insights for free - Jammu Links News
Should I hold or sell Elevation Oncology Inc. stock in 2025Invest smarter with daily trading signals - Jammu Links News
What drives Elevation Oncology Inc. stock priceUnlock your portfolio’s hidden potential - Jammu Links News
What are analysts’ price targets for Elevation Oncology Inc. in the next 12 monthsExplosive trading opportunities - Jammu Links News
How volatile is Elevation Oncology Inc. stock compared to the marketUnlock powerful stock screening tools today - Jammu Links News
When is Elevation Oncology Inc. stock expected to show significant growthTrack emerging stocks with high growth potential - Jammu Links News
What catalysts could drive Elevation Oncology Inc. stock higher in 2025Consistently high yield - Jammu Links News
Published on: 2025-07-30 03:27:50 - metal.it
Can trapped investors hope for a rebound in Elevation Oncology Inc.Entry Alert With Low Drawdown Strategy Noted - metal.it
Elevation Oncology Inc. Breaks Losing Streak — Is the Trend ReversingStep-by-Step Trade Signal Implementation Guide Ready - beatles.ru
How did ELEV's expenses impact profits in Q4 2024? - AInvest
What makes Elevation Oncology Inc. stock price move sharplyReal-Time Market Sentiment Tracking Gains Momentum - metal.it
Can trapped investors hope for a rebound in Elevation Oncology Inc. Bollinger Band Squeeze and Expansion Analysis - Newser
What makes Elevation Oncology Inc. stock price move sharply Short-Term Support and Resistance Forecast - Newser
Does Elevation Oncology Inc. stock perform well during market downturnsDiscover breakthrough stocks before the crowd - Jammu Links News
What are Elevation Oncology Inc. company’s key revenue driversFree Trend-Following Techniques - jammulinksnews.com
What are the technical indicators suggesting about Elevation Oncology Inc.High-yield investments - Jammu Links News
Intrinsic Value of Elevation Oncology Inc. Stock: Is It Undervalued or OvervaluedFree Investment Risk Control - Newser
How Interest Rate Changes Impact Elevation Oncology Inc. Stock PerformanceProfessional Stock Screener - Newser
How Efficient Is Elevation Oncology Inc. at Controlling Operating CostsFree Exclusive Group - beatles.ru
Why Elevation Oncology Inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $3.39 Average Price Target from Brokerages - Defense World
Is Elevation Oncology Inc. a good long term investmentFree Wealth Management Insights - Autocar Professional
Will Elevation Oncology Inc. stock benefit from AI tech trendsHigh-return market picks - jammulinksnews.com
Elevation Oncology completes merger with Concentra Biosciences, delists from Nasdaq - Investing.com
Elevation Oncology Completes Merger with Concentra Biosciences - TipRanks
Elevation Oncology, Inc. Announces Board Resignations - MarketScreener
Elevation Oncology Inc. Stock Analysis and ForecastSignificant capital appreciation - Autocar Professional
Elevation Oncology Inc Stock (ELEV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):